| Document |
Document Title |
|
WO/2024/134466A1 |
The present disclosure relates to substituted arylamine and substituted heteroarylamine compounds, analogues thereof, and compositions comprising the same. In one aspect, the compounds contemplated in the disclosure can be used to treat,...
|
|
WO/2024/132278A1 |
The present application relates to compounds of formula (I) for inhibiting FLT3. The present application further relates to a composition, preferably pharmaceutical composition, comprising a compound or a pharmaceutically acceptable salt...
|
|
WO/2024/138042A1 |
Described herein are α4β7 integrin inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of α4β7integrin-mediated conditions, such as inflammatory b...
|
|
WO/2024/131615A1 |
The present invention relates to a pharmaceutical composition comprising a first active ingredient and a second active ingredient, wherein the first active ingredient is compound 1, an ester corresponding thereto, a salt corresponding th...
|
|
WO/2024/130342A1 |
The present invention relates to compounds, pharmaceutical compositions of said compounds, and uses of said compounds, especially for inhibition of Transient Receptor Potential channel family, Vanilloid subfamily member 6 (TRPV6). The co...
|
|
WO/2024/132901A1 |
A compound of formula (I) wherein R1, R2, and G are as defined in claim 1, useful as pesticides, especially as fungicides.
|
|
WO/2024/133014A1 |
The present disclosure provides certain phenylpiperidine derivatives of formula (I), and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl -peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferas...
|
|
WO/2024/134516A1 |
The present invention relates to a novel compound as a protein kinase inhibitor, in particular, a RON inhibitor.
|
|
WO/2024/136689A1 |
The present invention relates to a method of preparing intermediates for the synthesis of opicapone, which comprises nitration of vanillic acid in an acid anhydride using a nitration agent. The present invention also relates to intermedi...
|
|
WO/2024/135589A1 |
Provided is a photoelectric conversion element in which a photoelectric conversion element material with which high sensitivity and high resolution can be achieved is used. The photoelectric conversion element comprises two electrodes an...
|
|
WO/2024/137984A1 |
Provided are compounds of the Formula (I) or pharmaceutically acceptable salts thereof, which are useful for the inhibition of KIF18A and in the treatment of a variety of KIF18A mediated conditions or diseases, such as cancer.
|
|
WO/2024/125437A1 |
The present invention belongs to the field of medicinal chemistry, and in particular relates to a compound that acts as a GSPT1 degradation agent, or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug thereof, a pre...
|
|
WO/2024/126773A1 |
A compound with the Formula (I): A-B-C wherein A is of the following formula (AA) and X1 is selected from O, S or NH; X2 is either N or C-H; X3 is either N or C-RA3; wherein if X1 is NH and X2 is C-H then X3 is C-RA3; B is of formula (B-...
|
|
WO/2024/128525A1 |
The present invention relates to a novel lipid compound and a lipid nanoparticle composition comprising same. More particularly, the lipid nanoparticle composition comprises ionized lipids, helper lipids, PEG-lipids, and additives, and c...
|
|
WO/2024/128305A1 |
The problem addressed by the present invention is to provide a novel compound that acts as an agonist on orexin 2 receptors and can be used in the treatment of diseases associated with the orexin 2 receptors, especially narcolepsy. Provi...
|
|
WO/2024/127297A1 |
Described herein are 3-fluoro-4-hydroxybenzamide-containing inhibitors and/or degraders, and pharmaceutical compositions containing 3-fluoro-hydroxybenzamide-containing inhibitors and/or degraders. In some embodiments, the 3-fluoro-4-hyd...
|
|
WO/2024/125626A1 |
The present invention discloses a nitrogenous compound, pharmaceutical composition and use thereof. The present invention provides a compound represented by formula (I) or formula (II), a solvate thereof, a pharmaceutically acceptable sa...
|
|
WO/2024/129601A1 |
Disclosed herein are compounds for use as muscle myosin inhibitors, along with methods for making and using the same. Compounds of the present disclosure can exhibit a selectivity for cardiac vs. skeletal myosin and do not inhibit non-mu...
|
|
WO/2024/124439A1 |
An antibacterial and anti-tumor synergist, and a synthesis method therefor and a use thereof. According to an antibacterial and anti-tumor synergist compound, the drug sensitivity of bacteria and tumor cells to antibiotics and anti-cance...
|
|
WO/2024/125488A1 |
Provided are an aromatic amide derivative, a preparation method therefor, and the pharmaceutical use of a pharmaceutical composition containing the derivative. Specifically, provided are an aromatic amide derivative as shown in general f...
|
|
WO/2024/125628A1 |
The present disclosure provides a phosphate ester prodrug of a Malt1 inhibitor. Specifically, the present disclosure provides a prodrug as represented by formula (I) or a pharmaceutically acceptable salt thereof and a use thereof in prep...
|
|
WO/2024/129634A1 |
Provided herein are compounds that modulate RMB39 and methods of using the compounds in RMB39-associated disorders, such as cancer (e.g., renal cell carcinoma).
|
|
WO/2024/129026A1 |
The invention relates to the use of ezetimibe drug active ingredient synthesis intermediates and iso-pazopanib hydrochloride salt compounds, which is the structural isomer of and pazopanib hydrochloride drug active ingredient (multiple k...
|
|
WO/2024/130095A1 |
Described herein are compounds of Formula I and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., for degrading certain proteins such as p300/CBP proteins).
|
|
WO/2024/125543A1 |
The present invention relates to a crystal form of darovasertib (hereinafter referred to as "compound I"), a method for preparing same, a pharmaceutical composition comprising the crystal form, and the use of the crystal form in treating...
|
|
WO/2024/126407A1 |
The current invention relates to compounds of the formula (I) wherein the substituents are as defined in claim 1, to processes and methods for preparing compounds of formula (I), to agrochemical compositions comprising compounds of formu...
|
|
WO/2024/124287A1 |
The present invention relates generally to a compound and/or a composition comprising the compound, useful for the treatment of, or prevention of, a Coronavirus (CoV) infection in particular SARS-CoV/SARS-CoV-1 or SARS-CoV-2.
|
|
WO/2024/125662A1 |
The present invention provides a preparation and application of a novel biaryl ring compound as an immunomodulator, and specifically, the present invention provides: a compound as shown in the following formula (I), or an optical isomer,...
|
|
WO/2024/130173A1 |
Disclosed are benzimidazole derivatives, pharmaceutical compositions comprising them, and methods of using them.
|
|
WO/2024/124279A1 |
The present disclosure relates to compounds useful as modulators of proton-activated G protein-coupled receptors, and pharmaceutical compositions comprising same. The present disclosure also relates to methods of using such compounds and...
|
|
WO/2024/124353A1 |
Disclosed are fused mescaline derivative compounds, comprising substituted ethylamine fused heterocyclic mescaline derivatives of formula (I) and (II), including substituted ethylamine fused dioxane and dioxolane mescaline derivatives, a...
|
|
WO/2024/126777A1 |
The specification relates to compounds of Formula (I) and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the tre...
|
|
WO/2024/120360A1 |
The present invention provides a PARP7 inhibitor compound represented by formula I, a preparation method therefor, and a use thereof in treating and/or preventing PARP7-mediated diseases.
|
|
WO/2024/121779A1 |
The invention relates to compounds of Formula (I) (I) and pharmaceutically acceptable salts thereof as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to inte...
|
|
WO/2024/119277A1 |
The disclosure relates to KRAS inhibitor compounds having the structure of Formula (I), pharmaceutical compositions thereof, and methods of use thereof for inhibiting, treating, and/or preventing KRAS-associated diseases, disorders and c...
|
|
WO/2024/121427A1 |
The present disclosure relates to compounds that are IL-17A modulators. The compounds have the structural Formula I defined herein. The present disclosure also relates to processes for the preparation of these compounds, to pharmaceutica...
|
|
WO/2024/121048A1 |
The present invention relates to compounds of formula (I) as defined in the specification capable of promoting the opening of Kv7.2/7.3 potassium channels, a pharmaceutical composition comprising them, and their use as a drug, particular...
|
|
WO/2024/121261A1 |
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.
|
|
WO/2024/122840A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2024/121046A1 |
The present invention relates to compounds of formula (I) as defined in the specification capable of promoting the opening of Kv7.2/Kv7.3 potassium channels, a pharmaceutical composition comprising them, and their use as a drug, particul...
|
|
WO/2024/121086A1 |
The invention relates to novel compounds having the general formula (I), wherein R1, R2, R3, R4, R5, and R6, are as described herein, composition including the compounds and methods of using the compounds.
|
|
WO/2024/122444A1 |
The present invention relates to a fluorine-containing isoxazole compound represented by general formula (A). (In general formula (A), R represents a hydrogen atom or a substituted or unsubstituted C1-12 hydrocarbon group, X represents a...
|
|
WO/2024/121138A1 |
The present invention relates to a crystalline form of 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop
yl- phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-
2-ol adipic acid salt and its use in the treatment or pr...
|
|
WO/2024/122617A1 |
The present invention provides a compound having an antagonist and/or inverse agonist action on the serotonin 5-HT2A receptor as well as an antagonist and/or inverse agonist action on the serotonin 5-HT2C receptor, or a pharmaceutically ...
|
|
WO/2024/122450A1 |
The present invention provides a compound having excellent control efficacy against harmful arthropods. A compound represented by formula (I) [wherein: R1 and R2 are the same or different and represent a C1-C6 chain hydrocarbon group, et...
|
|
WO/2024/115662A1 |
The present invention relates to a compound according to formula (I) and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions...
|
|
WO/2024/114787A1 |
Provided in the present application is a compound as represented by formula (I). The compound can regulate the KIF18A protein, thereby affecting the cell cycle and the cell proliferation process to treat cancer and cancer-associated dise...
|
|
WO/2024/118858A1 |
Provided are compounds of Formula I, Formula Ia and Formula Ib and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, Formula Ia an...
|
|
WO/2024/114568A1 |
Provided are a heterocyclic substituted pyrimidine compound, a preparation method therefor, and a use thereof. Specifically, provided is a heterocyclic substituted pyrimidine compound represented by formula (I) or a pharmaceutically acce...
|
|
WO/2024/115549A1 |
The present invention relates to compounds of Formula (I), their synthesis and use as CCR8 receptor modulators in medicine.
|
